Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone844-967-2633
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.45 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/27/2019 (Estimated)
OptionableOptionable
Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions
What is Oramed Pharmaceuticals' stock symbol?
Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
How were Oramed Pharmaceuticals' earnings last quarter?
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) issued its quarterly earnings results on Wednesday, July, 10th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.23). The biotechnology company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.71 million. Oramed Pharmaceuticals had a negative return on equity of 56.15% and a negative net margin of 568.43%. View Oramed Pharmaceuticals' Earnings History.
When is Oramed Pharmaceuticals' next earnings date?
What price target have analysts set for ORMP?
1 Wall Street analysts have issued 12-month target prices for Oramed Pharmaceuticals' stock. Their forecasts range from $25.00 to $25.00. On average, they expect Oramed Pharmaceuticals' stock price to reach $25.00 in the next year. This suggests a possible upside of 681.3% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.
What is the consensus analysts' recommendation for Oramed Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.
Has Oramed Pharmaceuticals been receiving favorable news coverage?
Press coverage about ORMP stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Oramed Pharmaceuticals.
Are investors shorting Oramed Pharmaceuticals?
Oramed Pharmaceuticals saw a decrease in short interest in July. As of July 31st, there was short interest totalling 38,900 shares, a decrease of 23.6% from the June 30th total of 50,900 shares. Based on an average daily volume of 42,900 shares, the short-interest ratio is presently 0.9 days. Approximately 0.3% of the shares of the company are short sold. View Oramed Pharmaceuticals' Current Options Chain.
Who are some of Oramed Pharmaceuticals' key competitors?
Some companies that are related to Oramed Pharmaceuticals include Kamada (KMDA), ProMetic Life Sciences (PFSCF), Ocular Therapeutix (OCUL), Evelo Biosciences (EVLO), Five Prime Therapeutics (FPRX), MannKind (MNKD), Calithera Biosciences (CALA), Athersys (ATHX), Constellation Pharmaceuticals (CNST), Cue Biopharma (CUE), Imprimis Pharmaceuticals (IMMY), Galectin Therapeutics (GALT), Spero Therapeutics (SPRO), Mustang Bio (MBIO) and AcelRx Pharmaceuticals (ACRX).
What other stocks do shareholders of Oramed Pharmaceuticals own?
Who are Oramed Pharmaceuticals' key executives?
Oramed Pharmaceuticals' management team includes the folowing people:
- Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
- Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
- Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
- Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board
Who are Oramed Pharmaceuticals' major shareholders?
Oramed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.91%) and Jane Street Group LLC (0.25%). Company insiders that own Oramed Pharmaceuticals stock include Aviad Friedman, Leonard Sank and Nadav Kidron. View Institutional Ownership Trends for Oramed Pharmaceuticals.
Which major investors are buying Oramed Pharmaceuticals stock?
ORMP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Jane Street Group LLC. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Aviad Friedman and Leonard Sank. View Insider Buying and Selling for Oramed Pharmaceuticals.
How do I buy shares of Oramed Pharmaceuticals?
Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oramed Pharmaceuticals' stock price today?
One share of ORMP stock can currently be purchased for approximately $3.20.
How big of a company is Oramed Pharmaceuticals?
Oramed Pharmaceuticals has a market capitalization of $55.62 million and generates $2.45 million in revenue each year. The biotechnology company earns $-12,720,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.
What is Oramed Pharmaceuticals' official website?
How can I contact Oramed Pharmaceuticals?
Oramed Pharmaceuticals' mailing address is 142 WEST 57TH STREET, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]
MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
